![Yoram Azulai](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Yoram Azulai is currently the Chief Executive Officer, CFO & Secretary at HBL- Hadasit Bio-Holdings Ltd. He is also a Director at Zingenix Ltd. and Tolaren Ltd. Previously, he served as a Director at ProtAb Ltd.
| Unternehmen | Position | Beginn |
|---|---|---|
Zingenix Ltd.
 Zingenix Ltd. BiotechnologyHealth Technology Provides gene therapy for orphan disorders | Direktor/Vorstandsmitglied | - |
Tolaren Ltd. | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
ProtAb Ltd.
 ProtAb Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutic agents that modulate cytokine regulation and tipping the balance toward anti-inflammatory signaling pathways | Direktor/Vorstandsmitglied | - |
| HBL - HADASIT BIO-HOLDINGS LTD | Vorstandsvorsitzender | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 4 |
|---|---|
HBL- Hadasit Bio-Holdings Ltd.
 HBL- Hadasit Bio-Holdings Ltd. Investment ManagersFinance Provides investment services in research and development companies for the medical & biotechnology sectors | Finance |
ProtAb Ltd.
ProtAb Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutic agents that modulate cytokine regulation and tipping the balance toward anti-inflammatory signaling pathways | Health Technology |
Zingenix Ltd.
Zingenix Ltd. BiotechnologyHealth Technology Provides gene therapy for orphan disorders | Health Technology |
Tolaren Ltd. |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
